|
|
|
FOR STUDY COORDINATORS
Welcome to the Study Coordinator's Section for INSTOR™ and INTRASTOR™. In this section, you will find information relevant to your participation in both registries, including instructions for enrollment, material to assist with IRB approval, tips for data collection, frequently asked questions and other valuable information.
Recognizing that many of you will work extra hours to collect the data, INSTOR™ reimburses the complete administrative cost of data collection on a per case basis. We suggest that some or all of the reimbursement be used to cover the Study Coordinator's time collecting and entering the data to our online data collection site. For additional information regarding reimbursement, please contact us.
At this time, data collection for INTRASTOR™ is not reimbursed. However, INTRASTOR™ is a short data form and does not require the same level of data collection.
INSTOR™
Medical and interventional therapy to effectively and efficiently treat acute ischemic stroke is undergoing rapid change. However, at present there is inadequate knowledge concerning the optimal appropriate drug, dose, patient population or timing for emergency interventional stroke therapy, even though there is increasing acknowledgment of the profound patient benefits achievable with this therapy. Combination pharmaceutical and/or mechanical/pharmaceutical therapies may ultimately result in the optimal means to treat acute stroke, just as has been determined to be the case concerning acute myocardial infarction.
INSTOR™ (INterventional Stroke Therapy Outcomes Registry™) is intended to be the definitive evaluation for interventional stroke therapy, comprising all means to optimally reverse the acute insult. This registry will provide a means to evaluate the safety and efficacy of presently performed interventions for acute stroke. Additionally, the optimal means to prevent secondary stroke and the primary prophylaxis of stroke are not defined in current medical practice and are also part of the subject of this registry.
INTRASTOR™
For over a decade, intracranial atherosclerotic disease has been treated by intracranial angioplasty/stenting, a procedure that has saved patients from or prevented many strokes. While the concept of improving blood flow to the brain by angioplasty and/or stenting has been explored in a rudimentary fashion, the improved technical capability to perform this procedure now mandates a closer look at this treatment option. This procedure is even now offering major benefit to large numbers of patients. While pilot trials evaluating intracranial stenting have been performed by industry, far more stenting procedures are performed than recorded and no record is being maintained concerning intracranial angioplasty whatsoever.
INTRASTOR™ (INTRacranial Angioplasty and Stenting Outcomes Registry™) is the second registry started under the auspices of the NeuroVascular Research Foundation (NVRF). This data acquisition registry will provide the evidence necessary to confirm that this procedure is equivalent to the concept of angioplasty and stenting in coronary vessels and will result in prevention of stroke.
INSTOR™II
INSTOR™II is similar to INSTOR but is specifically intended to document the efficacy and safety of treating acute ischemic stroke with intra-arterial ultrasound accelerated lytic therapy. Sites with ultrasound assisted interventional stroke therapy are invited to apply for participation in INSTOR™II.
Because the data collection is more extensive for INSTOR™II, this registry reimburses for the administrative cost of data collection on a per completed case basis. For additional information regarding reimbursement, please contact us.
Please join us in advancing the treatment of stroke.
|
|
